On July 14, PegBio (02565.HK) declined 8.11% in regular trading, trading at HKD 5.91/share, with turnover of HKD 121 million. The pullback follows a sharp rally driven by the company's memorandum of understanding with Nasdaq-listed Rani Therapeutics announced on July 8.

The stock had surged approximately 29% on July 10 and gained another 4% on July 13 after the two companies agreed to leverage Rani's proprietary RaniPill oral biologics delivery platform for oral formulation screening and preclinical development of PegBio's obesity and metabolic disease candidates. The partnership also covers potential R&D, manufacturing, and commercialization cooperation outside China under a three-year framework.

The current decline reflects concentrated profit-taking following the rapid cumulative gains. Market enthusiasm has moderated as participants reassess the timeline, noting the collaboration remains in its early screening phase with a lengthy path ahead before any substantive clinical advancement or commercialization milestones materialize.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)